Alluvi, previously BI 4744, presents a promising advance in weight control care. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates https://bookmarksystem.com/story21938160/alluvi-a-detailed-dive-into-the-medication-s-prospects